High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer

被引：0
|
作者：
Happel, C. [1 ]
Kranert, W. T. [1 ]
Bockisch, B. [1 ]
Groener, D. [1 ]
Davis, K. H. [1 ]
Wichert, J. [1 ]
Stefanova, M. [1 ]
Gruenwald, F. [1 ]
Sabet, A. [1 ]
机构：
[1] Univ Med Ctr Frankfurt, Dept Nucl Med, Frankfurt, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 46卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0580
引用
收藏
页码：S647 / S648
页数：2
相关论文
共 50 条
  • [21] Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
    Finn Edler von Eyben
    Giandomenico Roviello
    Timo Kiljunen
    Christian Uprimny
    Irene Virgolini
    Kalevi Kairemo
    Timo Joensuu
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 496 - 508
  • [22] Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing 177Lu-PSMA Therapy
    Ahmadzadehfar, Hojjat
    Essler, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) : 1033 - 1034
  • [23] Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
    von Eyben, Finn Edler
    Roviello, Giandomenico
    Kiljunen, Timo
    Uprimny, Christian
    Virgolini, Irene
    Kairemo, Kalevi
    Joensuu, Timo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 496 - 508
  • [24] Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
    Wenzel, Mike
    Koll, Florestan
    Hoeh, Benedikt
    Humke, Clara
    Siech, Carolin
    Mader, Nicolai
    Sabet, Amir
    Groener, Daniel
    Steuber, Thomas
    Graefen, Markus
    Maurer, Tobias
    Brandts, Christian
    Banek, Severine
    Chun, Felix K. H.
    Mandel, Philipp
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 61 - 66
  • [25] Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer
    Treiber, Hannes
    Koenig, Alexander
    Neesse, Albrecht
    Richter, Annika
    Sahlmann, Carsten Oliver
    Strauss, Arne
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (07) : 1016 - 1019
  • [26] 177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis
    Sadaghiani, Mohammad S.
    Sheikhbahaei, Sara
    Werner, Rudolf A.
    Pienta, Kenneth J.
    Pomper, Martin G.
    Gorin, Michael A.
    Solnes, Lilja B.
    Rowe, Steven P.
    PROSTATE, 2022, 82 (07): : 826 - 835
  • [27] First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Kao, Yung Hsiang
    Falzone, Nadia
    Pearson, Michael
    Sivaratnam, Dinesh
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2024, 52 (03)
  • [28] Comparative Analysis of 177Lu-PSMA Radioligand Therapy Efficacy in Metastatic Castration-Resistant Prostate Cancer: Impact of Taxane Chemotherapy Precedence
    Nazar, A.
    Srivastava, D.
    Ora, M.
    Barai, S.
    Gambhir, S.
    Pradhan, P.
    Arya, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S672 - S672
  • [29] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [30] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
12345